FTSE MIB
32.665,21 -944,64 (-2,81%) Dow Jones
38.589,16 -57,94 (-0,15%) Nasdaq
17.688,88 +21,32 (+0,12%) Nikkei 225
38.814,56 +94,09 (+0,24%) Petrolio
78,49 -0,13 (-0,17%) Bitcoin EUR
61.737,38 -31,64 (-0,05%)
Solid Biosciences Inc. (SLDB)
| Chiusura precedente | 8,51 |
| Aperto | 8,31 |
| Denaro | 7,87 x 200 |
| Domanda | 7,96 x 400 |
| Min-Max giorno | 7,81 - 8,44 |
| Intervallo di 52 settimane | 1,81 - 15,05 |
| Volume | |
| Media Volume | 224.252 |
| Capitalizzazione | 303,197M |
| Beta (mensile su 5 anni) | 1,87 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -3,93 |
| Prossima data utili | 12 ago 2024 - 16 ago 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 16,50 |
GlobeNewswireSolid Biosciences Appoints Gabriel Brooks, M.D., as Chief Medical Officer
- Dr. Brooks is a veteran drug development leader whose experience includes roles at Pfizer, 4D Molecular Therapeutics, and Gilead Life Sciences, which directly supports Solid’s focus on both neuromuscular and cardiac diseases - CHARLESTOWN, Mass., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for both neuromuscular and cardiac diseases, today announced the appointment of Gabriel Brooks, M.D., as Chief Medi
- GlobeNewswire
Solid Biosciences to Participate at Upcoming Investor Conferences
CHARLESTOWN, Mass., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief Executive Officer, will participate in the following three upcoming investor conferences: Jefferies Cell & Genetic Medicines Summit - New York, NYPresenting on Wednesday, September 27, 2023, at 10:00 AM ET.Cantor Global Healthcare Conference - New York, NYPresen
- GlobeNewswire
Solid Biosciences to Participate in Citi’s 18th Annual BioPharma Conference
CHARLESTOWN, Mass., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief Executive Officer, will present at the Citi 18th Annual BioPharma Conference on Thursday, September 7, 2023, at 9:40 AM ET. A live webcast of the presentation will be available on the Events page of the Investors section of the Company website or by clicking here
